PLX READ THE FULL PLX RESEARCH REPORT Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO ...
After a brief pause, gold is back on the rise. On Tuesday, it climbed above the $4,300 per ounce mark again, partly thanks to the weakness of the US dollar. When might we see new ...
Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the discovery, development, production and ...
Local leaders, students and others in San Jose, California, were stunned when a photograph of high school students forming a ...
The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $12.75 / share. This is a decrease of 10.71% from the prior estimate of $14.28 dated November 14, 2025.
On October 17, 2025, Protalix and Chiesi Global Rare Diseases, Protalix's partner in "the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or “the Company”) ...
NEW YORK, NY / ACCESS Newswire / October 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Protalix BioTherapeutics, Inc. ("Protalix BioTherapeutics, Inc.") ...
NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback